18680-27-8Relevant articles and documents
Synthesis of Thrombin Inhibitor DuP 714
Wityak, John,Earl, Richard A.,Abelman, Matthew M.,Bethel, Yvonne B.,Fisher, Barbara N.,et al.
, p. 3717 - 3722 (1995)
The asymmetric synthesis of thrombin inhibitor DuP 714 (1) is described.The route uses the Matteson boronic ester homologation to prepare the key intermediate, α-aminoboronic acid 4.New methodology was developed for the formamidination of boroornithine peptides and for pinanediol boronate ester cleavage.
Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib
Xu, Yulong,Yang, Xicheng,Chen, Yiyi,Chen, Hao,Sun, Huijiao,Li, Wei,Xie, Qiong,Yu, Linqian,Shao, Liming
supporting information, p. 2148 - 2152 (2018/05/25)
A series of structurally novel proteasome inhibitors 1–12 have been developed based rational topology-based scaffold hopping of bortezomib. Among these novel proteasome inhibitors, compound 10 represents an important advance due to the comparable proteasome-inhibitory activity (IC50 = 9.7 nM) to bortezomib (IC50 = 8.3 nM), the remarkably higher BEI and SEI values and the effectiveness in metabolic stability. Therefore, compound 10 provides an excellent lead suitable for further optimization.
A Modular Approach to the Asymmetric Synthesis of Cytisine
Struth, Felix R.,Hirschhaüser, Christoph
supporting information, p. 958 - 964 (2016/03/01)
The asymmetric synthesis of (+)-and (-)-cytisine starts with Matteson homologations for the construction of a chiral C3-building block. Conversion of the C3-building block into a dihydropyridone is achieved by straightforward functional group interconversions and ring closing metathesis. After bromination, this central building block was diastereospecifically converted into cytisine in five steps.